The potential role of glycogen synthase kinase 3 inhibitors as Amyotrophic lateral sclerosis pharmacological therapy

Current Medicinal Chemistry

Volumn 18, Issue 20, 2011, Pages 3028-3034

  Palomo, V ^a   Perez, D I ^a   Gil, C ^a   Martinez, A ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

Amyotrophic lateral sclerosis (ALS); GSK 3 inhibitors; Motor neurons; Neurodegenerative diseases

Indexed keywords

AR A 014418; ARIMOCLOMOL; BRX 345; CEFTRIAXONE; CK 2017357; EPIGALLOCATECHIN GALLATE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; KNS 760704; LITHIUM; LITHIUM CARBONATE; NORPHENAZONE; NP 001; OLESOXIME; PIOGLITAZONE; PRAMIPEXOLE; PYRIMETHAMINE; RASAGILINE; RETINOIC ACID; RILUZOLE; TIDEGLUSIB; UNCLASSIFIED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN INFARCTION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME INHIBITION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; INFLAMMATION; MALARIA; MOOD DISORDER; NEOPLASM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RESTLESS LEGS SYNDROME; REVIEW; RNA INTERFERENCE; SCORING SYSTEM; STROKE; TOXOPLASMOSIS; UNSPECIFIED SIDE EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 79959948402     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796391697     Document Type: Review

References (86)

1. Neru, R. The CNS market outlook to 2011. Business Insights 2006.
2. Scatena, R.; Martorana, G. E.; Bottoni, P.; Botta, G.; Pastore, P.; Giardina, B. An update on pharmacological approaches to neurodegenerative diseases. Expert Opin. Investig. Drugs, 2007, 16, 59-72 (Pubitemid 44964167)
3. Lomen-Hoerth, C. Amyotrophic lateral sclerosis from bench to bedside. Semin. Neurol., 2008, 28, 205-211 (Pubitemid 351438981)
4. Gordon, P. H. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management. CNS Drugs, 2011, 25, 1-15
5. Kurtzke, J. F. Epidemiology of amyotrophic lateral sclerosis. Adv. Neurol., 1982, 36, 281-302
6. Logroscino, G.; Traynor, B. J.; Hardiman, O.; Chio'a, A.; Couratier, P.; Mitchell, J. D.; Swingler, R. J.; Beghi, E. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J. Neurol. Neurosurg. Psychiatry, 2008, 79, 6-11
7. Kuzma-Kozakiewicz, M.; Kwiecinski, H. New therapeutic targets for amyotrophic lateral sclerosis. Expert Opin. Ther. Targets, 2011, 15, 127-143
8. Rosen, D. R.; Siddique, T.; Patterson, D.; Figlewicz, D. A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O'Regan, J. P.; Deng, H.-X.; Rahmani, Z.; Krizus, A.; McKenna-Yasek, D.; Cayabyab, A.; Gaston, S. M.; Berger, R.; Tanzi, R. E.; Halperin, J. J.; Herzfeldt, B.; Van den Bergh, R.; Hung, W.-Y.; Bird, T.; Deng, G.; Mulder, D. W.; Smyth, C.; Laing, N. G.; Soriano, E.; Pericak-Vance, M. A.; Haines, J.; Rouleau, G. A.; Gusella, J. S.; Horvitz, H. R.; Brown, R. H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 1993, 362, 59-62 (Pubitemid 23087289)
9. Swarup, V.; Julien, J.-P. ALS pathogenesis: Recent insights from genetics and mouse models. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, doi:10.1016/j.pnpbp. 2010.1008.1006
10. Bosco, D. A.; Landers, J. E. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets. CNS Neurol. Disord. Drug Targets, 2010, 9, 779-790
11. Belzil, V. V.; St-Onge, J.; Daoud, H.; Desjarlais, A.; Bouchard, J.-P.; Dupre, N.; Camu, W.; Dion, P. A.; Rouleau, G. A. Identification of a FUS splicing mutation in a large family with amyotrophic lateral sclerosis. J. Hum. Genet., 2010, doi:10.1038/jhg.2010.1162
12. Barmada, S. J.; Finkbeiner, S. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: diseaseassociated pathways. Rev. Neurosci., 2010, 21, 251-272
13. Liscic, R. M.; Breljak, D. Molecular basis of amyotrophic lateral sclerosis. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, doi:10.1016/j.pnpbp. 2010.1007.1017
14. Mackenzie, I. R.; Rademakers, R.; Neumann, M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol., 2010, 9, 995-1007
15. Goodall, E. F.; Morrison, K. E. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev. Mol. Med., 2006, 8, 1-22 (Pubitemid 43904876)
16. Rothstein, J. D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65, S3-S9
17. Bruijn, L. I.; Miller, T. M.; Cleveland, D. W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann. Rev. Neurosci., 2004, 27, 723-749 (Pubitemid 39050419)
18. Cheah, B. C.; Vucic, S.; Krishnan, A. V.; Kiernan, M. C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem., 2010, 17, 1942-1199
19. Zoccolella, S.; Santamato, A.; Lamberti, P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr. Dis. Treat., 2009, 5, 577-595
20. Traub, R.; Mitsumoto, H.; Rowland, L. P. Research advances in amyotrophic lateral sclerosis, 2009 to 2010. Curr. Neurol. Neurosci. Rep., 2011, 11, 67-77
21. Siciliano, G.; Carlesi, C.; Pasquali, L.; Piazza, S.; Pietracupa, S.; Fornai, F.; Ruggieri, S.; Murri, L. Clinical trials for neuroprotection in ALS. CNS Neurol. Disord. Drug Targets, 2010, 9, 305-313
22. Elliott, J. L. Experimental models of amyotrophic lateral sclerosis. Neurobiol. Dis., 1999, 6, 310-320 (Pubitemid 29496211)
23. Harvey, B. K.; Richie, C. T.; Hoffer, B. J.; Airavaara, M. Transgenic animal models of neurodegeneration based on human genetic studies. J. Neural. Transm., 2011, 118, 27-45
24. Kato, S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol., 2008, 115, 97-114 (Pubitemid 50003823)
25. Heiman-Patterson, T. D.; Sher, R. B.; Blankenhorn, E. A.; Alexander, G.; Deitch, J. S.; Kunst, C. B.; Maragakis, N.; Cox, G. Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers. Amyotroph. Lateral Scler., 2011, doi: 10.3109/17482968.17482010.17550626
26. Gurney, M. E.; Pu, H.; Chiu, A. Y.; Dal Canto, M. C.; Polchow, C. Y.; Alexander, D. D.; Caliendo, J.; Hentati, A.; Kwon, Y. W.; Deng, H. X.; Chen, W. J.; Zhai, P.; Sufit, R. L.; Siddique, T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science, 1994, 264, 1772-1775 (Pubitemid 24227760)
27. Benatar, M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis., 2007, 26, 1-13 (Pubitemid 46437445)
28. Neumann, M.; Sampathu, D. M.; Kwong, L. K.; Truax, A. C.; Micsenyi, M. C.; Chou, T. T.; Bruce, J.; Schuck, T.; Grossman, M.; Clark, C. M.; McCluskey, L. F.; Miller, B. L.; Masliah, E.; Mackenzie, I. R.; Feldman, H.; Feiden, W.; Kretzschmar, H. A.; Trojanowski, J. Q.; Lee, V. M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 2006, 314, 130-133 (Pubitemid 44547757)
29. Wegorzewska, I.; Baloh, R. H. TDP-43-Based Animal Models of Neurodegeneration: New Insights into ALS Pathology and Pathophysiology. Neurodegener. Dis., 2011, doi: 10.1159/000321547
30. Wegorzewska, I.; Bell, S.; Cairns, N. J.; Miller, T. M.; Baloh, R. H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA, 2009, 106, 18809-18814
31. Wils, H.; Kleinberger, G.; Janssens, J.; Pereson, S.; Joris, G.; Cuijt, I.; Smits, V.; Ceuterick-de Groote, C.; Van Broeckhoven, C.; Kumar-Singh, S. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA, 2010, 107, 3858-3863
32. Stallings, N. R.; Puttaparthi, K.; Luther, C. M.; Burns, D. K.; Elliott, J. L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis., 2010, 40, 404-414
33. Tsai, K. J.; Yang, C. H.; Fang, Y. H.; Cho, K. H.; Chien, W. L.; Wang, W. T.; Wu, T. W.; Lin, C. P.; Fu, W. M.; Shen, C. K. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J. Exp. Med., 2010, 207, 1661-1673
34. Xu, Y. F.; Gendron, T. F.; Zhang, Y. J.; Lin, W. L.; D'Alton, S.; Sheng, H.; Casey, M. C.; Tong, J.; Knight, J.; Yu, X.; Rademakers, R.; Boylan, K.; Hutton, M.; McGowan, E.; Dickson, D. W.; Lewis, J.; Petrucelli, L. Wildtype human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci., 2010, 30, 10851-10859
35. Shan, X.; Chiang, P. M.; Price, D. L.; Wong, P. C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl. Acad. Sci. USA, 2010, 107, 16325-16330
36. Ash, P. E.; Zhang, Y. J.; Roberts, C. M.; Saldi, T.; Hutter, H.; Buratti, E.; Petrucelli, L.; Link, C. D. Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum. Mol. Genet., 2010, 19, 3206-3218
37. Li, Y.; Ray, P.; Rao, E. J.; Shi, C.; Guo, W.; Chen, X.; Woodruff, E. A., 3rd; Fushimi, K.; Wu, J. Y. A Drosophila model for TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA, 2010, 107, 3169-3174
38. Hanson, K. A.; Kim, S. H.; Wassarman, D. A.; Tibbetts, R. S. Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS). J. Biol. Chem., 2010, 285, 11068-11072
39. Ritson, G. P.; Custer, S. K.; Freibaum, B. D.; Guinto, J. B.; Geffel, D.; Moore, J.; Tang, W.; Winton, M. J.; Neumann, M.; Trojanowski, J. Q.; Lee, V. M.; Forman, M. S.; Taylor, J. P. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J. Neurosci., 2010, 30, 7729-7739
40. Murch, S. J.; Cox, P. A.; Banack, S. A.; Steele, J. C.; Sacks, O. W. Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol. Scand., 2004, 110, 267-269 (Pubitemid 39274063)
41. Cox, P. A.; Richer, R.; Metcalf, J. S.; Banack, S. A.; Codd, G. A.; Bradley, W. G. Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. Amyotroph. Lateral Scler., 2009, 10 Suppl 2, 109-117
42. Karamyan, V. T.; Speth, R. C. Animal models of BMAA neurotoxicity: a critical review. Life Sci., 2008, 82, 233-246
43. Zhou, X.; Escala, W.; Papapetropoulos, S.; Bradley, W. G.; Zhai, R. G. BMAA neurotoxicity in Drosophila. Amyotroph. Lateral Scler., 2009, 10 Suppl 2, 61-66
44. Cox, P. A.; Banack, S. A. A nonprotein amino acid and neurodegeneration. Science, 2006, 314, 1242
45. Bär, P. R. Motor neuron disease in vitro: the use of cultured motor neurons to study amyotrophic lateral sclerosis. Eur. J. Pharmacol., 2000, 405, 285-295
46. Jackson, M.; Ganel, R.; Rothstein, J. D. Models of amyotrophic lateral sclerosis. Curr. Protoc. Neurosci., 2002, Chapter 9, Unit 9 13
47. Tomatsuri, N.; Yoshida, N.; Takagi, T.; Katada, K.; Isozaki, Y.; Imamoto, E.; Uchiyama, K.; Kokura, S.; Ichikawa, H.; Naito, Y.; Okanoue, T.; Yoshikawa, T. Edaravone, a newly developed radical scavenger, protects against ischemia-reperfusion injury of the small intestine in rats. Int. J. Mol. Med., 2004, 13, 105-109
48. Rothstein, J. D.; Patel, S.; Regan, M. R.; Haenggeli, C.; Huang, Y. H.; Bergles, D. E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D. S.; Toan, S. V.; Bruijn, L. I.; Su, Z. Z.; Gupta, P.; Fisher, P. B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433, 73-77 (Pubitemid 40101145)
49. http://www.knoppneurosciences.com
50. Martin, L. J. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs, 2010, 13, 568-580
51. Phukan, J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs, 2010, 13, 482-496
52. www.clinicaltrials.gov (Clinical trial NCT00561366)
53. www.clinicaltrials.gov (Clinical trial NCT01083667)
54. Phukan, S.; Babu, V. S.; Kannoji, A.; Hariharan, R.; Balaji, V. N. GSK3beta: role in therapeutic landscape and development of modulators. Br. J. Pharmacol., 2010, 160, 1-19
55. Hooper, C.; Killick, R.; Lovestone, S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem., 2008, 104, 1433-1439 (Pubitemid 351316776)
56. Martinez, A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev., 2008, 28, 773-796
57. Martinez, A.; Perez, D. I. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J. Alzheimers Dis., 2008, 15, 181-191
58. Wada, A. GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front. Biosci., 2009, 14, 1558-1570
59. Jope, R. S. In: Glycogen synthase kinase 3 (GSK-3) and its inhibitors. Martinez, A., Castro, A. and Medina, M. Eds., Ed.; John Wiley & Sons: Hoboken, New Jersey, 2006, pp. 223-242.
60. Alonso, M.; Martinez, A. GSK-3 inhibitors: discoveries and developments. Curr. Med. Chem., 2004, 11, 755-763 (Pubitemid 38380049)
61. Hamann, M.; Alonso, D.; Martin-Aparicio, E.; Fuertes, A.; Perez-Puerto, M. J.; Castro, A.; Morales, S.; Navarro, M. L.; Del Monte-Millan, M.; Medina, M.; Pennaka, H.; Balaiah, A.; Peng, J.; Cook, J.; Wahyuono, S.; Martinez, A. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J. Nat. Prod., 2007, 70, 1397-1405 (Pubitemid 47584577)
62. Alonso, D.; Martinez, A. In: Glycogen synthase kinase 3 (GSK-3) and its inhibitors. Martinez, A., Castro, A. and Medina, M. Eds., Ed.; John Wiley & Sons: Hoboken, New Jersey, 2006, pp. 307-331.
63. Kaidanovich-Beilin, O.; Eldar-Finkelman, H. Peptides targeting protein kinases: strategies and implications. Physiology, 2006, 21, 411-418 (Pubitemid 44879250)
64. Atilla-Gokcumen, G. E.; Pagano, N.; Streu, C.; Maksimoska, J.; Filippakopoulos, P.; Knapp, S.; Meggers, E. Extremely tight binding of a ruthenium complex to glycogen synthase kinase 3. ChemBioChem, 2008, 9, 2933-2936
65. Martinez, A.; Alonso, M.; Castro, A.; Dorronsoro, I. In: In Medicinal Chemistry of Alzheimer's disease. Martinez, A. E., Ed.; Martinez, A. Ed. Transworld Research Network: Kerala, 2008, pp. 225-253.
66. Pérez, D. I.; Palomo, V.; Pérez, C.; Gil, C.; Dans, P.; Luque, F. J.; Conde, S.; Martinez, A. Switching reversibility to irreversibility in GSK-3 inhibitors: clues for specific design of new compounds. J. Med. Chem., 2011, doi. 10.1021/jm1016279
67. Hu, J. H.; Zhang, H.; Wagey, R.; Krieger, C.; Pelech, S. L. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem., 2003, 85, 432-442 (Pubitemid 36438338)
68. Yang, W.; Leystra-Lantz, C.; Strong, M. J. Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res., 2008, 1196, 131-139
69. Kihira, T.; Suzuki, A.; Kondo, T.; Wakayama, I.; Yoshida, S.; Hasegawa, K.; Garruto, R. M. Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients. Neuropathology, 2009, 29, 548-558
70. Koh, S. H.; Kwon, H.; Kim, K. S.; Kim, J.; Kim, M. H.; Yu, H. J.; Kim, M.; Lee, K. W.; Do, B. R.; Jung, H. K.; Yang, K. W.; Appel, S. H.; Kim, S. H. Epigallocatechin gallate prevents oxidative-stress-induced death of mutant Cu/Zn-superoxide dismutase (G93A) motoneuron cells by alteration of cell survival and death signals. Toxicology, 2004, 202, 213-225 (Pubitemid 39165396)
71. Koh, S. H.; Lee, Y. B.; Kim, K. S.; Kim, H. J.; Kim, M.; Lee, Y. J.; Kim, J.; Lee, K. W.; Kim, S. H. Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. Eur. J. Neurosci., 2005, 22, 301-309 (Pubitemid 41097603)
72. Chung, Y. H.; Joo, K. M.; Kim, D. J.; Kim, S. S.; Kim, K. Y.; Lee, W. B.; Cha, C. I. Immunohistochemical study on the distribution of glycogen synthase kinase 3alpha in the central nervous system of SOD1 (G93A) transgenic mice. Neurol. Res., 2008, 30, 926-931
73. Rowe, M. K.; Wiest, C.; Chuang, D. M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci. Biobehav. Rev., 2007, 31, 920-931 (Pubitemid 47285347)
74. Stambolic, V.; Ruel, L.; Woodgett, J. R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol., 1996, 6, 1664-1668 (Pubitemid 27050234)
75. Klein, P. S.; Melton, D. A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA, 1996, 93, 8455-8459 (Pubitemid 26269579)
76. De Sarno, P.; Li, X.; Jope, R. S. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology, 2002, 43, 1158-1164 (Pubitemid 36009369)
77. Sugai, F.; Yamamoto, Y.; Miyaguchi, K.; Zhou, Z.; Sumi, H.; Hamasaki, T.; Goto, M.; Sakoda, S. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci., 2004, 20, 3179-3183 (Pubitemid 40007312)
78. Shin, J. H.; Cho, S. I.; Lim, H. R.; Lee, J. K.; Lee, Y. A.; Noh, J. S.; Joo, I. S.; Kim, K. W.; Gwag, B. J. Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis. Mol. Pharmacol., 2007, 71, 965-975
79. Calderó, J.; Brunet, N.; Tarabal, O.; Piedrafita, L.; Hereu, M.; Ayala, V.; Esquerda, J. E. Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience, 2010, 165, 1353-1369
80. Feng, H. L.; Leng, Y.; Ma, C. H.; Zhang, J.; Ren, M.; Chuang, D. M. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience, 2008, 155, 567-572
81. Leng, Y.; Liang, M. H.; Ren, M.; Marinova, Z.; Leeds, P.; Chuang, D. M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci., 2008, 28, 2576-2588 (Pubitemid 351348211)
82. Koh, S. H.; Lee, S. M.; Kim, H. Y.; Lee, K. Y.; Lee, Y. J.; Kim, H. T.; Kim, J.; Kim, M. H.; Hwang, M. S.; Song, C.; Yang, K. W.; Lee, K. W.; Kim, S. H.; Kim, O. H. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci. Lett., 2006, 395, 103-107 (Pubitemid 43188873)
83. Naerum, L.; Norskov-Lauritsen, L.; Olesen, P. H. Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett., 2002, 12, 1525-1528 (Pubitemid 34521927)
84. Koh, S. H.; Kim, Y.; Kim, H. Y.; Hwang, S.; Lee, C. H.; Kim, S. H. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp. Neurol., 2007, 205, 336-346 (Pubitemid 46755762)
85. Fornai, F.; Longone, P.; Cafaro, L.; Kastsiuchenka, O.; Ferrucci, M.; Manca, M. L.; Lazzeri, G.; Spalloni, A.; Bellio, N.; Lenzi, P.; Modugno, N.; Siciliano, G.; Isidoro, C.; Murri, L.; Ruggieri, S.; Paparelli, A. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA, 2008, 105, 2052-2057 (Pubitemid 351439463)
86. Chiò, A.; Borghero, G.; Calvo, A.; Capasso, M.; Caponnetto, C.; Corbo, M.; Giannini, F.; Logroscino, G.; Mandrioli, J.; Marcello, N.; Mazzini, L.; Moglia, C.; Monsurro, M. R.; Mora, G.; Patti, F.; Perini, M.; Pietrini, V.; Pisano, F.; Pupillo, E.; Sabatelli, M.; Salvi, F.; Silani, V.; Simone, I. L.; Soraru, G.; Tola, M. R.; Volanti, P.; Beghi, E. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology, 2010, 75, 619-625.